vs
Side-by-side financial comparison of Deckers Brands (DECK) and Jazz Pharmaceuticals plc (JAZZ). Click either name above to swap in a different company.
Deckers Brands is the larger business by last-quarter revenue ($2.0B vs $1.2B, roughly 1.6× Jazz Pharmaceuticals plc). Deckers Brands runs the higher net margin — 24.6% vs 17.0%, a 7.6% gap on every dollar of revenue. On growth, Jazz Pharmaceuticals plc posted the faster year-over-year revenue change (10.1% vs 7.1%). Deckers Brands produced more free cash flow last quarter ($1.0B vs $345.8M). Over the past eight quarters, Deckers Brands's revenue compounded faster (42.8% CAGR vs 15.2%).
Deckers Outdoor Corporation, doing business as Deckers Brands, is an American footwear designer and distributor founded in 1973 and based in Goleta, California. The company's portfolio of brands includes UGG, Teva, and Hoka. It was founded by Doug Otto and Karl F. Lopker.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
DECK vs JAZZ — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.0B | $1.2B |
| Net Profit | $481.1M | $203.5M |
| Gross Margin | 59.8% | — |
| Operating Margin | 31.4% | 21.2% |
| Net Margin | 24.6% | 17.0% |
| Revenue YoY | 7.1% | 10.1% |
| Net Profit YoY | 5.3% | 6.5% |
| EPS (diluted) | $3.33 | $3.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.0B | $1.2B | ||
| Q3 25 | $1.4B | $1.1B | ||
| Q2 25 | $964.5M | $1.0B | ||
| Q1 25 | $1.0B | $897.8M | ||
| Q4 24 | $1.8B | $1.1B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $825.3M | $1.0B | ||
| Q1 24 | $959.8M | $902.0M |
| Q4 25 | $481.1M | $203.5M | ||
| Q3 25 | $268.2M | $251.4M | ||
| Q2 25 | $139.2M | $-718.5M | ||
| Q1 25 | $151.4M | $-92.5M | ||
| Q4 24 | $456.7M | $191.1M | ||
| Q3 24 | $242.3M | $215.1M | ||
| Q2 24 | $115.6M | $168.6M | ||
| Q1 24 | $127.5M | $-14.6M |
| Q4 25 | 59.8% | — | ||
| Q3 25 | 56.2% | — | ||
| Q2 25 | 55.8% | — | ||
| Q1 25 | 56.7% | — | ||
| Q4 24 | 60.3% | — | ||
| Q3 24 | 55.9% | — | ||
| Q2 24 | 56.9% | — | ||
| Q1 24 | 56.2% | — |
| Q4 25 | 31.4% | 21.2% | ||
| Q3 25 | 22.8% | 5.1% | ||
| Q2 25 | 17.1% | -65.6% | ||
| Q1 25 | 17.0% | -6.2% | ||
| Q4 24 | 31.0% | 17.5% | ||
| Q3 24 | 23.3% | 24.7% | ||
| Q2 24 | 16.1% | 19.5% | ||
| Q1 24 | 15.0% | 7.3% |
| Q4 25 | 24.6% | 17.0% | ||
| Q3 25 | 18.7% | 22.3% | ||
| Q2 25 | 14.4% | -68.7% | ||
| Q1 25 | 14.8% | -10.3% | ||
| Q4 24 | 25.0% | 17.6% | ||
| Q3 24 | 18.5% | 20.4% | ||
| Q2 24 | 14.0% | 16.5% | ||
| Q1 24 | 13.3% | -1.6% |
| Q4 25 | $3.33 | $3.34 | ||
| Q3 25 | $1.82 | $4.08 | ||
| Q2 25 | $0.93 | $-11.74 | ||
| Q1 25 | $-2.78 | $-1.52 | ||
| Q4 24 | $3.00 | $2.97 | ||
| Q3 24 | $1.59 | $3.42 | ||
| Q2 24 | $4.52 | $2.49 | ||
| Q1 24 | $4.82 | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.1B | $1.4B |
| Total DebtLower is stronger | — | $5.4B |
| Stockholders' EquityBook value | $2.6B | $4.3B |
| Total Assets | $4.1B | $11.7B |
| Debt / EquityLower = less leverage | — | 1.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1B | $1.4B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | $1.7B | $1.2B | ||
| Q1 25 | $1.9B | $1.9B | ||
| Q4 24 | $2.2B | $2.4B | ||
| Q3 24 | $1.2B | $2.2B | ||
| Q2 24 | $1.4B | $1.4B | ||
| Q1 24 | $1.5B | $1.4B |
| Q4 25 | — | $5.4B | ||
| Q3 25 | — | $5.4B | ||
| Q2 25 | — | $5.4B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | — | $6.1B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | — | $5.7B | ||
| Q1 24 | — | $5.7B |
| Q4 25 | $2.6B | $4.3B | ||
| Q3 25 | $2.5B | $4.0B | ||
| Q2 25 | $2.5B | $3.7B | ||
| Q1 25 | $2.5B | $4.2B | ||
| Q4 24 | $2.6B | $4.1B | ||
| Q3 24 | $2.2B | $4.2B | ||
| Q2 24 | $2.1B | $3.8B | ||
| Q1 24 | $2.1B | $3.7B |
| Q4 25 | $4.1B | $11.7B | ||
| Q3 25 | $3.8B | $11.4B | ||
| Q2 25 | $3.8B | $10.9B | ||
| Q1 25 | $3.6B | $11.5B | ||
| Q4 24 | $4.0B | $12.0B | ||
| Q3 24 | $3.4B | $12.3B | ||
| Q2 24 | $3.3B | $11.4B | ||
| Q1 24 | $3.1B | $11.3B |
| Q4 25 | — | 1.24× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | — | 1.45× | ||
| Q1 25 | — | 1.29× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | 1.47× | ||
| Q2 24 | — | 1.52× | ||
| Q1 24 | — | 1.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.0B | $362.5M |
| Free Cash FlowOCF − Capex | $1.0B | $345.8M |
| FCF MarginFCF / Revenue | 52.1% | 28.9% |
| Capex IntensityCapex / Revenue | 1.1% | 1.4% |
| Cash ConversionOCF / Net Profit | 2.17× | 1.78× |
| TTM Free Cash FlowTrailing 4 quarters | $929.1M | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.0B | $362.5M | ||
| Q3 25 | $8.1M | $474.6M | ||
| Q2 25 | $36.1M | $88.9M | ||
| Q1 25 | $-73.0M | $429.8M | ||
| Q4 24 | $1.1B | $398.6M | ||
| Q3 24 | $-90.5M | $398.7M | ||
| Q2 24 | $112.7M | $331.4M | ||
| Q1 24 | $-28.7M | $267.2M |
| Q4 25 | $1.0B | $345.8M | ||
| Q3 25 | $-13.9M | $459.4M | ||
| Q2 25 | $12.2M | $75.9M | ||
| Q1 25 | $-89.4M | $415.9M | ||
| Q4 24 | $1.1B | $385.3M | ||
| Q3 24 | $-113.4M | $388.0M | ||
| Q2 24 | $90.1M | $324.3M | ||
| Q1 24 | $-44.0M | $260.3M |
| Q4 25 | 52.1% | 28.9% | ||
| Q3 25 | -1.0% | 40.8% | ||
| Q2 25 | 1.3% | 7.3% | ||
| Q1 25 | -8.8% | 46.3% | ||
| Q4 24 | 58.6% | 35.4% | ||
| Q3 24 | -8.6% | 36.8% | ||
| Q2 24 | 10.9% | 31.7% | ||
| Q1 24 | -4.6% | 28.9% |
| Q4 25 | 1.1% | 1.4% | ||
| Q3 25 | 1.5% | 1.3% | ||
| Q2 25 | 2.5% | 1.2% | ||
| Q1 25 | 1.6% | 1.5% | ||
| Q4 24 | 1.3% | 1.2% | ||
| Q3 24 | 1.7% | 1.0% | ||
| Q2 24 | 2.7% | 0.7% | ||
| Q1 24 | 1.6% | 0.8% |
| Q4 25 | 2.17× | 1.78× | ||
| Q3 25 | 0.03× | 1.89× | ||
| Q2 25 | 0.26× | — | ||
| Q1 25 | -0.48× | — | ||
| Q4 24 | 2.40× | 2.09× | ||
| Q3 24 | -0.37× | 1.85× | ||
| Q2 24 | 0.97× | 1.97× | ||
| Q1 24 | -0.22× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DECK
| UGG Brand Segment | $1.3B | 67% |
| Hoka Brand Segment | $628.9M | 32% |
| Other Brands Segment | $23.2M | 1% |
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
